We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

43 hedge funds and large institutions have $3.83M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

10% more funds holding

Funds holding: 39 → 43 (+4)

38% less capital invested

Capital invested by funds: $6.13M → $3.83M (-$2.3M)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
5
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$48.4K
2
LPL Financial
LPL Financial
California
+$28.1K
3
GW
GW & Wade
Massachusetts
+$23.7K
4
BFA
BlackRock Fund Advisors
California
+$12.1K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$9.08K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$280K
2
Millennium Management
Millennium Management
New York
-$177K
3
SM
Sabby Management
Florida
-$59.8K
4
CC
Cannell & Co
New York
-$52K
5
Renaissance Technologies
Renaissance Technologies
New York
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$6K +$47 +100 +0.7%
BA
27
BlackRock Advisors
Delaware
$6K +$6.78K +14,312 New
MC
28
Marcus Capital
Illinois
$6K +$7.11K +15,000 New
FCI
29
Financial Counselors Inc
Kansas
$5K – – –
PCM
30
Princeton Capital Management
New Jersey
$4K -$7.11K -15,000 -60%
EC
31
Estate Counselors
Wisconsin
$4K +$4.74K +10,000 New
FAAS
32
First Allied Advisory Services
California
$4K +$4.74K +10,000 New
Morgan Stanley
33
Morgan Stanley
New York
$1K -$412 -870 -34%
Citigroup
34
Citigroup
New York
$1K – – –
FWM
35
Focused Wealth Management
New York
$1K – – –
GT
36
Glenmede Trust
Pennsylvania
$1K – – –
LTFS
37
Ladenburg Thalmann Financial Services
Florida
$1K – – –
CC
38
Cannell & Co
New York
– -$52K -90,000 Closed
Renaissance Technologies
39
Renaissance Technologies
New York
– -$9K -16,300 Closed
MFBTD
40
MB Financial Bank - Trust Department
Illinois
– -$6K -10,000 Closed
Deutsche Bank
41
Deutsche Bank
Germany
– -$3.55K -7,500 -79%
TIM
42
Tortoise Investment Management
New York
– -$1K -2,000 Closed
Wells Fargo
43
Wells Fargo
California
– -$948 -2,000 -100%
TRCT
44
Tower Research Capital (TRC)
New York
– +$168 +355 New
BlackRock
45
BlackRock
New York
– +$427 +900 New
1
2

PVCT Hedge Fund Activity: Q4 2015 in Review

43 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2015, worth a combined $3.83M — down 38% from $6.13M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PVCT positions and 4 closed out — a net gain of 5 holders — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $48.4K. The largest seller was Goldman Sachs, cutting an estimated $280K.

  • 43 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2015, up from 39 in Q3 2015.
  • Funds reported $3.83M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2015, down 38% quarter-over-quarter.
  • 9 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2015 and 4 closed out, a net change of +5 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q4 2015 was Vanguard Group, an estimated $48.4K added.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2015 was Goldman Sachs, an estimated $280K sold.

Based on aggregated 13F filings for Q4 2015.